Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: A double-blind prospective, randomized, placebo-controlled pilot study

Rheumatology

Volumn 49, Issue 3, 2009, Pages 583-587

  Nguyen, Van Anh ^a   Eisendle, Klaus ^a   Gruber, Ingrid ^a   Hugl, Beate ^a   Reider, Daniela ^a   Reider, Norbert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Bosentan; Clinical trial; Endothelin receptor antagonist; HAQ disability index; Raynaud's phenomenon; Systemic sclerosis; United Kingdom functional score

Indexed keywords

BOSENTAN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; HUMAN; PAIN ASSESSMENT; PERIPHERAL EDEMA; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SKIN ULCER; SYSTEMIC SCLEROSIS; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; RAYNAUD DISEASE; RECEPTORS, ENDOTHELIN; SCLERODERMA, SYSTEMIC; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77950529138     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep413     Document Type: Article

References (20)

1. Wigley FM. Clinical practice. Raynaud's Phenomenon. N Engl J Med 2002;347:1001-8.
2. Kahaleh MB. Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 2004;16:718-22.
3. Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology 2005;44:587-96.
4. Mayes MD. Endothelin and endothelin receptor antago-nists in systemic rheumatic disease. Arthritis Rheum 2003; 48:1190-9.
5. Black CM, Denton CP. The management of systemic sclerosis. Br J Rheumatol 1995;34:3-7.
6. Korn JH, Mayes M, Matucci Cerinic M et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
7. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
8. Steen VD, Medsger TA Jr. The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
9. Merkel PA, Herlyn K, Martin RW et al. Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Bosentan in RP and SSc Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-20.
10. Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology 2003;42:191-3.
11. Ramos-Casals M, Brito-Zerón P, Nardi N et al. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology 2004;43:1454-6.
12. Snyder MJ, Jacobs MR, Grau RG, Wilkes DS, Knox KS. Resolution of severe digital ulceration during a course of Bosentan therapy. Ann Intern Med 2005;142:802-3.
13. Tillon J, Hervé F, Chevallier D, Muir JF, Levesque H, Marie I. Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy. Br J Dermatol 2006;154:1000-2.
14. Yu EP, Ostor AJ, Hall FC. Successful treatment with bosentan for severe digital ischaemia in limited cutaneous systemic sclerosis. Ann Rheum Dis 2007;66:1122-3.
15. Chamaillard M, Heliot-Hosten I, Constans J, Taïeb A. Bosentan as a rescue therapy in scleroderma refractory digital ulcers. Arch Dermatol 2007;143:125-6.
16. Matucci-Cerinic M, Denton CP, Furst DE et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis (abstract). Ann Rheum Dis 2006;65:A3-49.
17. Launay D, Diot E, Pasquier E et al. [Bosentan for treatment of active digital ulcers in patients with systemic sclerosis]. Presse Med 2006;35:587-92.
18. García de la Peña-Lefebvre P, Rodríguez Rubio S, Valero Expósito M et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology 2008;47:464-6.
19. Selenko-Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan. Rheumatology 2006;45(Suppl. 3):iii45-8.
20. Moore TL, Vail A, Herrick AL. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. Rheumatology 2007;46:363-4.